ID
37354
Description
Study ID: 111592 Clinical Study ID: 111592 Study Title: A Randomized, Double-blind, Placebo-controlled, Doseescalation Study to Assess the Anti-inflammatory Activity, Efficacy, and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury or ARDS Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00996840 See https://clinicaltrials.gov/ct2/show/NCT00996840 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Placebo, SB-681323 Trade Name: N/A Study Indication: Lung Injury, Acute The primary objective of this phase 2 trial is to evaluate the safety and tolerability of intravenous dilmapimod/SB-681323 given in escalating dosages and over different intervals for three days in trauma patients at risk for the development of ALI or ARDS. This study consists of Screening, infusion of dilmapimod/SB-681323 on days 1-3, examination/sampling up to early day 5 (denoted as "Day 3 - 48 hrs") and a Follow-up on day 7. There are four cohorts, cohorts 1 and 3 receive the medication (or placebo) infusion over 4 hours, cohorts 2 and 4 over 24 hours. This form contains details on the administration of the investigational product and is to be filled in at Day 1, 2 and 3. Additionally, this form also contains Randomisation information and the assignment of the participant to one of the four cohorts for/prior to the first medication administration.
Link
https://clinicaltrials.gov/ct2/show/NCT00996840
Keywords
Versions (2)
- 7/16/19 7/16/19 -
- 7/20/19 7/20/19 -
Copyright Holder
GlaxoSmithKline
Uploaded on
July 20, 2019
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
SB-681323 in ALI/ARDS risk patients - NCT00996840
Investigational Product - IV Dosing, Randomisation, Cohort Assignment
Description
First Administration
Alias
- UMLS CUI-1
- C3469597
Description
Cohorts 1/3: 0-4 hrs Cohorts 2/4: 0-24hrs
Data type
integer
Alias
- UMLS CUI [1,1]
- C0449238
- UMLS CUI [1,2]
- C3469597
- UMLS CUI [1,3]
- C0304229
Description
Start Date and Time
Data type
datetime
Alias
- UMLS CUI [1]
- C3897500
Description
Stop Date and Time
Data type
datetime
Alias
- UMLS CUI [1]
- C3899266
Description
Volume administered
Data type
float
Measurement units
- mL
Alias
- UMLS CUI [1]
- C2349139
Description
Administration post interruption
Alias
- UMLS CUI-1
- C3469597
- UMLS CUI-2
- C0687676
- UMLS CUI-3
- C1512900
Description
Cohorts 1/3: 0-4 hrs Cohorts 2/4: 0-24 hrs
Data type
integer
Alias
- UMLS CUI [1,1]
- C0449238
- UMLS CUI [1,2]
- C3469597
- UMLS CUI [1,3]
- C0304229
Description
Start Date and Time
Data type
datetime
Alias
- UMLS CUI [1]
- C3897500
Description
Stop Date and Time
Data type
datetime
Alias
- UMLS CUI [1]
- C3899266
Description
Volume administered
Data type
float
Measurement units
- mL
Alias
- UMLS CUI [1]
- C2349139
Description
Investigational Product Container Number
Alias
- UMLS CUI-1
- C0304229
- UMLS CUI-2
- C0180098
- UMLS CUI-3
- C0600091
Description
Treatment Confirmation
Alias
- UMLS CUI-1
- C0750484
- UMLS CUI-2
- C0087111
Description
If no, record reasons
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0087111
- UMLS CUI [1,2]
- C2349182
Description
if applicable
Data type
text
Alias
- UMLS CUI [1,1]
- C0566251
- UMLS CUI [1,2]
- C0087111
- UMLS CUI [1,3]
- C3827420
Description
Randomisation Number
Alias
- UMLS CUI-1
- C0034656
- UMLS CUI-2
- C0237753
Description
If yes, provide Randomisation Number and Date/time of randomisation
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0034656
- UMLS CUI [1,2]
- C0332149
Description
if applicable
Data type
integer
Alias
- UMLS CUI [1,1]
- C0034656
- UMLS CUI [1,2]
- C0237753
Description
if applicable
Data type
datetime
Alias
- UMLS CUI [1,1]
- C0034656
- UMLS CUI [1,2]
- C1264639
Similar models
Investigational Product - IV Dosing, Randomisation, Cohort Assignment
C1516050 (UMLS CUI [1,2])
C1264639 (UMLS CUI [1,3])
C3469597 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,3])
C0687676 (UMLS CUI-2)
C1512900 (UMLS CUI-3)
C3469597 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,3])
C0180098 (UMLS CUI-2)
C0600091 (UMLS CUI-3)
C0180098 (UMLS CUI [1,2])
C0600091 (UMLS CUI [1,3])
C0087111 (UMLS CUI-2)
C2349182 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,2])
C3827420 (UMLS CUI [1,3])
C0332149 (UMLS CUI [1,2])
C0237753 (UMLS CUI [1,2])
C1264639 (UMLS CUI [1,2])
No comments